SEC Comment Letter 0000000000-24-002809 to Oncternal Therapeutics, Inc. (ONCT) (CIK 0001260990)
Oncternal Therapeutics, Inc. (ONCT) (CIK 0001260990)
Date: March 14, 2024 · CIK: 0001260990 · Accession: 0000000000-24-002809
AI Filing Summary & Sentiment
File numbers found in text: 333-277795
Letter
United States securities and exchange commission logo March 14, 2024 James B. Breitmeyer, M.D., Ph.D. Chief Executive Officer Oncternal Therapeutics, Inc. 12230 El Camino Real, Suite 230 San Diego, CA 92130 Re:Oncternal Therapeutics, Inc. Registration Statement on Form S-3 Filed March 8, 2024 File No. 333-277795 Dear James B. Breitmeyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anthony A. Gostanian, Esq.
Show Raw Text
United States securities and exchange commission logo
March 14, 2024
James B. Breitmeyer, M.D., Ph.D.
Chief Executive Officer
Oncternal Therapeutics, Inc.
12230 El Camino Real, Suite 230
San Diego, CA 92130
Re:Oncternal Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 8, 2024
File No. 333-277795
Dear James B. Breitmeyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anthony A. Gostanian, Esq.